ArticleAmerican journal of translational research2015
Molecular docking and inhibition of matrix metalloproteinase-2 by novel difluorinatedbenzylidene curcumin analog.
Article in American journal of translational research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Computational Repurposing of FDA-Approved Drugs as Candidate MMP2 Inhibitors with Putative MMP3 Cross-Activity.International journal of molecular sciences · 2026Article
- Novel C3/C28-bis-1,2,4-Triazolyl-sulfanylacetate-betulin Derivatives: Synthesis and Evaluation of Anticancer Potential.International journal of molecular sciences · 2026Article
- Curcumin and Its Derivatives as Anticancer Agents in Head and Neck Cancer: Molecular Mechanisms and Preclinical Evidence.International journal of molecular sciences · 2026Review
- Atorvastatin ameliorates chronic subdural hematomas by interrupting the 'chronic subdural hematoma cycle' via inhibition of the inflammatory response.Experimental and therapeutic medicine · 2026Article
- Exploration of isolated actives from Coleus amboinicus leaves as anticancer agents: in vitro testing, network pharmacology studies, and molecular docking.Scientific reports · 2025Article
- Harnessing the metastatic potential of human osteosarcoma cells by natural coumarin galbanic acid.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Inhibition of MMP-2 and MMP-9 by Dietary Antioxidants in THP-1 Macrophages and Sera from Patients with Breast Cancer.Molecules (Basel, Switzerland) · 2024Article
- Chlorin E6-Curcumin-Mediated Photodynamic Therapy Promotes an Anti-Photoaging Effect in UVB-Irradiated Fibroblasts.International journal of molecular sciences · 2023Article
- Anti-Inflammatory Effects of Dietary Polyphenols through Inhibitory Activity against Metalloproteinases.Molecules (Basel, Switzerland) · 2023Review
- Anticancer Activity of Novel Difluorinated Curcumin Analog and Its Inclusion Complex with 2-Hydroxypropyl-β-Cyclodextrin against Pancreatic Cancer.International journal of molecular sciences · 2023Article
- Synergistic effects of dendrosomal nanocurcumin and oxaliplatin on oncogenic properties of ovarian cancer cell lines by down-expression of MMPs.Biological research · 2023Article
- miR-874: An Important Regulator in Human Diseases.Frontiers in cell and developmental biology · 2022Review
- COP9 signalosome is an essential and druggable parasite target that regulates protein degradation.PLoS pathogens · 2020Article
- In Ovo and In Silico Evaluation of the Anti-Angiogenic Potential of Syringin.Drug design, development and therapy · 2020Article
- Review
- Article
- The Role of Curcumin in Prevention and Management of Metastatic Disease.International journal of molecular sciences · 2018Review
- Anti-metastatic effects of isolinderalactone via the inhibition of MMP-2 and up regulation of NM23-H1 expression in human lung cancer A549 cells.Oncology letters · 2018Article
- Review
- Cancer Chemoprevention by Phytochemicals: Nature's Healing Touch.Molecules (Basel, Switzerland) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
We recently described the synthesis and characterization of a novel difluorinatedbenzylidene analog of curcumin, commonly referred as CDF, which demonstrated significantly enhanced bioavailability and in vivo anticancer activity. CDF targets many factors similar to curcumin, albeit with more potency, as reported previously. To further highlight this differential behavior of CDF, we chose matrix metalloproteinase protein MMP-2 which is involved in the processes of invasion and metastasis of human tumors. Both curcumin and CDF were characterized for their binding characteristics using in silico docking studies; they were also evaluated via biological assays involving gelatin zymography, miRNA analysis, invasion assays and ELISA. CDF was found to inhibit MMP-2 expression and activity in A549 and H1299 NSCLC cells much more effectively than curcumin, validating molecular modeling results. miR-874, an MMP-2-targeting miRNA, was up-regulated by CDF. Thus, it appears that CDF can inhibit MMP-2 through multiple mechanisms. Our results are suggestive of a more potent inhibition of invasion and metastasis by CDF, compared to curcumin, thus warranting its further evaluation as an effective anticancer agent.
Indexed as
Identifiers
25901198PMC4399093W300485825What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.